Dual antiplatelet therapy (DAPT), including aspirin and an oral inhibitor of the platelet P2Y ₁₂ receptor, is the standard of treatment after percutaneous coronary intervention (PCI) to mitigate the risks of stent-related and stent-unrelated ischemic events, including myocardial infarction (MI), stroke, and cardiovascular death. However, prolonged DAPT carries a heightened risk of bleeding, which has been shown to be associated with a downstream increase in mortality, morbidity, and cost. Shorter-duration DAPT was thought to be reasonable, especially with the use of “newer-generation” drug-eluting stents (DES), which have thinner stent struts and improved biocompatibility and drug delivery. These stents were shown to be associated with lower rates of stent thrombosis and MI compared to “first-generation” DES. Nevertheless, the DAPT needle hasn't moved very dramatically. For the most part, patients receiving PCI with DES associated with an acute coronary syndrome (ACS) are still receiving DAPT for one year, or longer, in the absence of high bleeding risk, AND patients receiving PCI with DES in a stable coronary artery disease (CAD) setting without ACS are still receiving DAPT for at least 6 months.